Cargando…
Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study
PURPOSE: Daily quantitative MR imaging during radiotherapy of cancer patients has become feasible with MRI systems integrated with linear accelerators (MR-linacs). Quantitative images could be used for treatment response monitoring. With intravoxel incoherent motion (IVIM) MRI, it is possible to acq...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415108/ https://www.ncbi.nlm.nih.gov/pubmed/34485138 http://dx.doi.org/10.3389/fonc.2021.705964 |
_version_ | 1783747906004582400 |
---|---|
author | Kooreman, Ernst S. van Houdt, Petra J. Keesman, Rick van Pelt, Vivian W. J. Nowee, Marlies E. Pos, Floris Sikorska, Karolina Wetscherek, Andreas Müller, Arndt-Christian Thorwarth, Daniela Tree, Alison C. van der Heide, Uulke A. |
author_facet | Kooreman, Ernst S. van Houdt, Petra J. Keesman, Rick van Pelt, Vivian W. J. Nowee, Marlies E. Pos, Floris Sikorska, Karolina Wetscherek, Andreas Müller, Arndt-Christian Thorwarth, Daniela Tree, Alison C. van der Heide, Uulke A. |
author_sort | Kooreman, Ernst S. |
collection | PubMed |
description | PURPOSE: Daily quantitative MR imaging during radiotherapy of cancer patients has become feasible with MRI systems integrated with linear accelerators (MR-linacs). Quantitative images could be used for treatment response monitoring. With intravoxel incoherent motion (IVIM) MRI, it is possible to acquire perfusion information without the use of contrast agents. In this multicenter study, daily IVIM measurements were performed in prostate cancer patients to identify changes that potentially reflect response to treatment. MATERIALS AND METHODS: Forty-three patients were included, treated with 20 fractions of 3 Gy on a 1.5 T MR-linac. IVIM measurements were performed on each treatment day. The diffusion coefficient (D), perfusion fraction (f), and pseudo-diffusion coefficient (D*) were calculated based on the median signal intensities in the non-cancerous prostate and the tumor. Repeatability coefficients (RCs) were determined based on the first two treatment fractions. Separate linear mixed-effects models were constructed for the three IVIM parameters. RESULTS: In total, 726 fractions were analyzed. Pre-treatment average values, measured on the first fraction before irradiation, were 1.46 × 10(−3) mm(2)/s, 0.086, and 28.7 × 10(−3) mm(2)/s in the non-cancerous prostate and 1.19 × 10(−3) mm(2)/s, 0.088, and 28.9 × 10(−3) mm(2)/s in the tumor, for D, f, and D*, respectively. The repeatability coefficients for D, f, and D* in the non-cancerous prostate were 0.09 × 10(−3) mm(2)/s, 0.05, and 15.3 × 10(−3) mm(2)/s. In the tumor, these values were 0.44 × 10(−3) mm(2)/s, 0.16, and 76.4 × 10(−3) mm(2)/s. The mixed effects analysis showed an increase in D of the tumors over the course of treatment, while remaining stable in the non-cancerous prostate. The f and D* increased in both the non-cancerous prostate and tumor. CONCLUSIONS: It is feasible to perform daily IVIM measurements on an MR-linac system. Although the repeatability coefficients were high, changes in IVIM perfusion parameters were measured on a group level, indicating that IVIM has potential for measuring treatment response. |
format | Online Article Text |
id | pubmed-8415108 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84151082021-09-04 Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study Kooreman, Ernst S. van Houdt, Petra J. Keesman, Rick van Pelt, Vivian W. J. Nowee, Marlies E. Pos, Floris Sikorska, Karolina Wetscherek, Andreas Müller, Arndt-Christian Thorwarth, Daniela Tree, Alison C. van der Heide, Uulke A. Front Oncol Oncology PURPOSE: Daily quantitative MR imaging during radiotherapy of cancer patients has become feasible with MRI systems integrated with linear accelerators (MR-linacs). Quantitative images could be used for treatment response monitoring. With intravoxel incoherent motion (IVIM) MRI, it is possible to acquire perfusion information without the use of contrast agents. In this multicenter study, daily IVIM measurements were performed in prostate cancer patients to identify changes that potentially reflect response to treatment. MATERIALS AND METHODS: Forty-three patients were included, treated with 20 fractions of 3 Gy on a 1.5 T MR-linac. IVIM measurements were performed on each treatment day. The diffusion coefficient (D), perfusion fraction (f), and pseudo-diffusion coefficient (D*) were calculated based on the median signal intensities in the non-cancerous prostate and the tumor. Repeatability coefficients (RCs) were determined based on the first two treatment fractions. Separate linear mixed-effects models were constructed for the three IVIM parameters. RESULTS: In total, 726 fractions were analyzed. Pre-treatment average values, measured on the first fraction before irradiation, were 1.46 × 10(−3) mm(2)/s, 0.086, and 28.7 × 10(−3) mm(2)/s in the non-cancerous prostate and 1.19 × 10(−3) mm(2)/s, 0.088, and 28.9 × 10(−3) mm(2)/s in the tumor, for D, f, and D*, respectively. The repeatability coefficients for D, f, and D* in the non-cancerous prostate were 0.09 × 10(−3) mm(2)/s, 0.05, and 15.3 × 10(−3) mm(2)/s. In the tumor, these values were 0.44 × 10(−3) mm(2)/s, 0.16, and 76.4 × 10(−3) mm(2)/s. The mixed effects analysis showed an increase in D of the tumors over the course of treatment, while remaining stable in the non-cancerous prostate. The f and D* increased in both the non-cancerous prostate and tumor. CONCLUSIONS: It is feasible to perform daily IVIM measurements on an MR-linac system. Although the repeatability coefficients were high, changes in IVIM perfusion parameters were measured on a group level, indicating that IVIM has potential for measuring treatment response. Frontiers Media S.A. 2021-08-13 /pmc/articles/PMC8415108/ /pubmed/34485138 http://dx.doi.org/10.3389/fonc.2021.705964 Text en Copyright © 2021 Kooreman, van Houdt, Keesman, van Pelt, Nowee, Pos, Sikorska, Wetscherek, Müller, Thorwarth, Tree and van der Heide https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Kooreman, Ernst S. van Houdt, Petra J. Keesman, Rick van Pelt, Vivian W. J. Nowee, Marlies E. Pos, Floris Sikorska, Karolina Wetscherek, Andreas Müller, Arndt-Christian Thorwarth, Daniela Tree, Alison C. van der Heide, Uulke A. Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study |
title | Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study |
title_full | Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study |
title_fullStr | Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study |
title_full_unstemmed | Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study |
title_short | Daily Intravoxel Incoherent Motion (IVIM) In Prostate Cancer Patients During MR-Guided Radiotherapy—A Multicenter Study |
title_sort | daily intravoxel incoherent motion (ivim) in prostate cancer patients during mr-guided radiotherapy—a multicenter study |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8415108/ https://www.ncbi.nlm.nih.gov/pubmed/34485138 http://dx.doi.org/10.3389/fonc.2021.705964 |
work_keys_str_mv | AT kooremanernsts dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT vanhoudtpetraj dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT keesmanrick dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT vanpeltvivianwj dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT noweemarliese dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT posfloris dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT sikorskakarolina dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT wetscherekandreas dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT mullerarndtchristian dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT thorwarthdaniela dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT treealisonc dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy AT vanderheideuulkea dailyintravoxelincoherentmotioniviminprostatecancerpatientsduringmrguidedradiotherapyamulticenterstudy |